Drug Profile
AP 2200
Alternative Names: AP2200Latest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator Arissa Pharma
- Class
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for phase-I development in Pain(In volunteers) in Unknown (PO)
- 03 Jun 2016 Phase-I clinical trials in Pain (In volunteers) (PO) before June 2016